Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-386 in Healthy Volunteers
NCT05552495Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ezetimibe + rosuvastatin + telmisartan in hypertension (HTN) and dyslipidemia (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the Last Quantifiable Concentration and Maximum Plasma Concentration. Started Sep 2022; status: completed.
02
Drugs
ezetimibe + rosuvastatin + telmisartan
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT05552495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552495.